Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) said a routine inspection of its wholly owned step-down subsidiary, Lannett Co. in Seymour, Indiana, by U.S. Food and Drug Administration, concluded with four observations.
The inspection was conducted from Aug. 17 to 21, according to a Monday filing on NSE. The company said the observations were procedural in nature and it will respond to the U.S. FDA within the specified timeline.